BRISTOL MYERS SQUIBB

Bristol Myers Squibb's schizophrenia drug, Cobenfy, approved by FDA; CEO Chris Boerner calls it a 'new pharmacological approach' with potential to 'change the treatment paradigm'; shares rose 2%.

FDA approves Cobenfy, a new schizophrenia treatment combining xanomeline and trospium chloride, targeting cholinergic receptors, offering a new alternative to traditional antipsychotics.

Bristol Myers Squibb's new schizophrenia drug, Cobenfy, approved by FDA, represents a new approach in decades. The drug, a muscarinic receptor agonist, differs from current treatments with fewer side effects.

Emily Jarvie, a journalist with experience in political, business, legal, and scientific reporting, joined Proactive in 2022. Proactive provides global investment news, covering markets like biotech, mining, and digital technologies. The company uses technology to enhance workflows but maintains human authorship for all content.

Bristol-Myers Squibb's COBENFY, a new schizophrenia treatment, received FDA approval, marking the first new pharmacological approach in decades. The drug targets M1 and M4 receptors, with a favorable safety profile and potential peak sales of $4.2 billion.

The FDA approved Cobenfy, a new schizophrenia treatment by Bristol-Myers Squibb, targeting muscarinic acetylcholine receptors to avoid common dopamine-blocker side effects. Expected to be available next month at $1,850 per 30-day supply, it could generate over $6 billion in annual sales.

FDA approves Bristol Myers Squibb's Cobenfy, the first new class of schizophrenia treatment in over 3 decades, targeting M1 and M4 receptors without blocking D2 receptors.

New imaging technologies and improved use of existing ones may advance precision medicine in inflammatory arthritis, according to Georg Schett, MD, at the 2024 Congress of Clinical Rheumatology West. Schett highlighted the potential of machine learning and MRI for diagnosing undifferentiated arthritis and differentiating between conditions like psoriatic arthritis and rheumatoid arthritis. He also discussed the use of high-resolution CT for bone mass determination and treatment efficacy checks, emphasizing the need for a 3D approach over conventional X-rays. Schett noted the infancy of functional imaging and introduced new technologies like multispectral optoacoustic tomography (MSOT) for entheseal tissue visualization in PsA and psoriasis patients. He concluded by suggesting that understanding tissue response in inflammation, such as with fibroblast activation protein inhibitors, could guide therapeutic decisions.

Bristol Myers Squibb and 2seventy bio halt KarMMa-9 trial enrollment due to fewer eligible patients, attributed to advances in induction therapies leading to higher complete response rates in newly diagnosed multiple myeloma patients post-transplant.

FDA approves Cobenfy, a new schizophrenia drug that affects dopamine indirectly via cholinergic receptors, offering an alternative to current dopamine-focused medications with fewer side effects like weight gain and sluggishness. Initial trials show symptom reduction, but long-term effectiveness and safety remain uncertain. Cobenfy will cost $1,850 a month.